NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
The last earnings update was 58 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether NOXXON Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NOXXON Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NOXXON Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NOXXON Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
NOXXON Pharma has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of 0N6’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through NOXXON Pharma's regulatory filings and announcements.
Unable to determine if NOXXON Pharma is high growth as no earnings estimate data is available.
NOXXON Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NOXXON Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Aram Mangasarian has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma AG since July 1, 2015 and served as its has been Chief Business Officer since May 18, 2010 and serves as its Member of Executive Board. Dr. Mangasarian is responsible for corporate and business development activities for NOXXON. He has more than 10 years of business development and strategic planning experience within the biotechnology and pharmaceutical industry. He served as Vice President of Business Development of Novexel SA. Dr. Mangasarian joined Novexel SA group from another French firm, ExonHit Therapeutics SA, a publicly traded French drug discovery and development company, where he spent over five years in business development, most recently as Vice President of Business Development. During this time, Dr. Mangasarian identified strategic partners, negotiated alliances and was responsible for marketing and sales of research products. He led the team that built strategic alliances and negotiated research agreements with a number of pharmaceutical companies. A key part of his role at ExonHit was the development of commercialization strategies. Dr. Mangasarian concluded a number of licensing and research agreements and prepared Novexel SA towards IPO. During his time in the laboratory of Didier Trono, he led two different teams in research projects in virology. He has contributed to several scientific publications including Nature Cell Biology and the Journal of Virology. Prior to ExonHit, he held a postdoctoral fellowship at The University of Geneva Medical School in the Department of Genetics and Microbiology from 1997 to 1999. As graduate of the University of California, San Diego, Dr. Mangasarian earned his PhD in the Department of Biology by conducting research on HIV. He holds an MBA, from Insead.
Aram's compensation has increased whilst company is loss making.
Aram's remuneration is about average for companies of similar size in Germany.
CEO & Member of Management Board
Chief Medical Officer & Member of Management Board
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the NOXXON Pharma board of directors is less than 3 years, this suggests a new board.
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.